Abstract
BackgroundFor patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care regimens without clear and established biomarkers to inform...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have